STCube is a Seoul-based biotechnology company developing precision immunotherapies for difficult-to-treat, resistant and recurrent cancers. Its central program is nelmastobart, described as the first anti-BTN1A1 immune-checkpoint inhibitor, developed through collaboration with institutions including MD Anderson Cancer Center. The company completed its first-in-human Phase 1 trial and is advancing biomarker-driven studies in colorectal and non-small-cell lung cancers.
Innovative Cellular TherapeuticsHeadquartered in Rockville, Innovative Cellular Therapeutics is a private clinical-stage biotechnology company developing cellular immunotherapies for solid tumors. Its proprietary CoupledCAR® platform underpins individually made CAR-T therapies, including the lead GCC19CART program being studied for relapsed or refractory metastatic colorectal cancer. Founded by Larry Lei Xiao and Zoe Zhao Wu, ICT combines more than 20 years of stem-cell, cell-therapy and gene-editing experience with FDA cellular-therapy review expertise.ROCKVILLE, MD
BeyondSpringFounded in 2010, BeyondSpring is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies, centered on its investigational lead asset Plinabulin. The Florham Park company is advancing Plinabulin as a GEF-H1 agonist that promotes dendritic-cell maturation and may help re-sensitize tumors after checkpoint-inhibitor treatment while reducing chemotherapy-induced neutropenia. Its development program has treated more than 700 cancer patients and includes the confirmatory DUBLIN-4 Phase 3 program in non-small-cell lung cancer.NEW YORK, NY
Sator Therapeutics LLCCleveland-based Sator Therapeutics develops naturally occurring, non-pathogenic oncolytic viruses intended to selectively kill cancer cells in hard-to-treat tumors. Its preclinical platform combines a library of nearly 30 human enterovirus strains with systemic delivery, sequential dosing, companion diagnostics, and a patented dendritic-cell carrier. The company’s approach is protected by four issued U.S. patents and a Japanese patent, while its lead mesothelioma program advances toward formal clinical development.CLEVELAND, OH
Facili Bio LLCFacili Bio LLC uses an AI-powered drug-discovery platform and proprietary computational biology to develop new cancer treatments. The company focuses on difficult areas of oncology, pairing research into patient-specific therapies with clinical studies intended to move promising discoveries toward patients.ALBANY, NY